BR112016029460A2 - métodos para tratar artrite reumatoide - Google Patents

métodos para tratar artrite reumatoide

Info

Publication number
BR112016029460A2
BR112016029460A2 BR112016029460A BR112016029460A BR112016029460A2 BR 112016029460 A2 BR112016029460 A2 BR 112016029460A2 BR 112016029460 A BR112016029460 A BR 112016029460A BR 112016029460 A BR112016029460 A BR 112016029460A BR 112016029460 A2 BR112016029460 A2 BR 112016029460A2
Authority
BR
Brazil
Prior art keywords
methods
rheumatoid arthritis
treat rheumatoid
treating
treat
Prior art date
Application number
BR112016029460A
Other languages
English (en)
Portuguese (pt)
Inventor
Masteller Emma
Xiang Hong
Zanghi James
Hambleton Julie
Sikorski Robert
Original Assignee
Five Prime Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Five Prime Therapeutics Inc filed Critical Five Prime Therapeutics Inc
Publication of BR112016029460A2 publication Critical patent/BR112016029460A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112016029460A 2014-06-23 2015-06-18 métodos para tratar artrite reumatoide BR112016029460A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462015710P 2014-06-23 2014-06-23
PCT/US2015/036419 WO2015200089A1 (en) 2014-06-23 2015-06-18 Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)

Publications (1)

Publication Number Publication Date
BR112016029460A2 true BR112016029460A2 (pt) 2017-10-24

Family

ID=53674259

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016029460A BR112016029460A2 (pt) 2014-06-23 2015-06-18 métodos para tratar artrite reumatoide

Country Status (13)

Country Link
US (2) US10975153B2 (enExample)
EP (1) EP3157957A1 (enExample)
JP (2) JP6964410B2 (enExample)
KR (2) KR20230086809A (enExample)
CN (2) CN106795222A (enExample)
AU (1) AU2015280362B2 (enExample)
BR (1) BR112016029460A2 (enExample)
CA (1) CA2951156A1 (enExample)
EA (1) EA037561B1 (enExample)
IL (1) IL249393B (enExample)
MX (1) MX391735B (enExample)
SG (2) SG11201610672YA (enExample)
WO (1) WO2015200089A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130302322A1 (en) * 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
CN110709422B (zh) * 2017-04-19 2023-12-26 马伦戈治疗公司 多特异性分子及其用途
CN109053887B (zh) * 2018-07-18 2019-07-23 博奥信生物技术（南京）有限公司 一种抗人csf-1r单克隆抗体及用途
CN108948199B (zh) * 2018-07-18 2019-06-21 博奥信生物技术（南京）有限公司 抗人csf-1r单克隆抗体及其用途
EP3833762A4 (en) 2018-08-09 2022-09-28 Verseau Therapeutics, Inc. Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
US11419822B2 (en) * 2020-12-14 2022-08-23 AmMax Bio, Inc. High concentration formulations of anti-CSF1 and anti-CSF1R antibodies

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JP2518911B2 (ja) 1987-10-23 1996-07-31 森永乳業株式会社 ｃ―ｆｍｓ癌原遺伝子の過剰発現によって特徴づけられた癌の処置用組成物および方法
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5866114A (en) 1992-06-09 1999-02-02 Chiron Corporation Crystallization of M-CSFα
US20020193575A1 (en) 1993-09-07 2002-12-19 Smithkline Beecham P.L.C. Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
JPH10218791A (ja) 1997-01-31 1998-08-18 Toagosei Co Ltd 慢性関節リウマチ治療薬
US6972323B1 (en) 1997-04-01 2005-12-06 Sankyo Company, Limited Anti-Fas antibodies
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
WO1999029345A1 (en) 1997-12-05 1999-06-17 La Jolla Institute For Experimental Medicine Inhibition of tumor growth by macrophage intervention
WO2000025803A1 (en) 1998-10-30 2000-05-11 Takeda Chemical Industries, Ltd. Betacellulin protein-containing preparations
KR20020027311A (ko) 1999-05-07 2002-04-13 제넨테크, 인크. Ｂ 세포 표면 마커에 결합하는 길항물질을 이용한자가면역 질환의 치료
JP4307775B2 (ja) 1999-10-28 2009-08-05 ゼイェトホサイン・アハリネヤート Ｃｓｆ−１インヒビターの使用
AU1759501A (en) 1999-11-08 2001-06-06 Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The Method of treating a viral infection using antagonists of macrophage colony stimulating factor
US7108852B2 (en) 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
US7455836B2 (en) 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
US6773895B2 (en) 2000-09-01 2004-08-10 Boehringer Ingelheim Pharma Kg Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases
US7247618B2 (en) 2001-04-30 2007-07-24 Tripathi Rajavashisth Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling
AU2002314495A1 (en) 2001-06-20 2003-01-02 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
CA2505994A1 (en) 2002-11-15 2004-06-03 Chiron Corporation Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
WO2005040395A1 (en) 2003-10-22 2005-05-06 Keck Graduate Institute Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy
GB0325836D0 (en) 2003-11-05 2003-12-10 Celltech R&D Ltd Biological products
EP1706137A2 (en) 2004-01-21 2006-10-04 Chiron Corporation M-csf muteins and uses thereof
CA2565974A1 (en) 2004-05-14 2005-12-01 Receptor Biologix, Inc. Cell surface receptor isoforms and methods of identifying and using the same
WO2006012451A2 (en) 2004-07-22 2006-02-02 Five Prime Therapeutics, Inc. Compositions and methods of use for mgd-csf in disease treatment
WO2006076288A2 (en) 2005-01-11 2006-07-20 Five Prime Therapeutics, Inc. Dna constructs for long-term expression of intravascularly injected naked dna
ATE454455T1 (de) 2005-01-27 2010-01-15 Five Prime Therapeutics Inc Leitsequenzen zur anleitung von polypeptidsekretion und verfahren zur herstellung
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
RU2008123518A (ru) 2005-11-10 2009-12-20 Ресептор Байолоджикс, Инк. (Us) Способы получения изоформ рецепторов и лигандов
WO2007075933A2 (en) 2005-12-21 2007-07-05 Cell Signaling Technology, Inc. Translocation and mutant csf1r kinase in human leukemia
CA2634945A1 (en) 2005-12-22 2007-10-25 Novartis Ag Soluble human m-csf receptor and uses thereof
RU2470665C2 (ru) 2006-01-05 2012-12-27 Новартис Аг Способы профилактики и лечения ракового метастаза и разрежения кости, связанного с раковым метастазом
AU2007248493B2 (en) 2006-05-04 2010-09-30 The Rockefeller University HCV coreceptor and methods of use thereof
US7833789B2 (en) 2006-08-01 2010-11-16 Fondazione Centro San Raffaele Del Monte Tabor Monocyte cell
EP2089049A4 (en) 2006-11-17 2011-11-16 Biogen Idec Inc SYSTEMIC ADMINISTRATION OF COLONIAL STIMULATING FACTORS TO TREAT AMYLOID ASSOCIATED DISEASES
US7919594B2 (en) 2007-02-14 2011-04-05 Vaccinex, Inc. Human anti-CD100 antibodies
WO2008124858A2 (en) 2007-04-11 2008-10-23 F-Star Biotechnologische Forschungs- Und Entwicklungsges. M.B.H. Targeted receptor
WO2008150383A1 (en) 2007-05-30 2008-12-11 Albert Einstein College Of Medicine Of Yeshiva University Csf-1r mutants
CN101802008B (zh) 2007-08-21 2015-04-01 安美基公司 人类c-fms抗原结合蛋白
US7981415B2 (en) 2007-09-07 2011-07-19 Cisthera, Inc. Humanized PAI-1 antibodies
JP2011502266A (ja) 2007-10-31 2011-01-20 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｆｍｓ治療に対する応答を評価するバイオマーカー
WO2009075344A1 (ja) 2007-12-12 2009-06-18 Japan As Represented By Director General Of Agency Of National Cancer Center M-csf受容体を分子標的とするmll白血病及びmoz白血病治療剤、およびその利用
US8470977B2 (en) 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
AU2009224955B2 (en) 2008-03-14 2012-08-09 Transgene S.A. Antibody against the CSF-1 R
WO2010062399A2 (en) 2008-11-26 2010-06-03 Five Prime Therapeutics, Inc. Csf1r extracellular domain fusion molecules and treatments using same
US8183207B2 (en) 2008-11-26 2012-05-22 Five Prime Therapeutics, Inc. Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules
PT2949670T (pt) 2009-12-10 2019-05-20 Hoffmann La Roche Anticorpos que se ligam preferencialmente ao domínio extracelular 4 do csf1r e respetiva utilização
CA2789071C (en) 2010-03-05 2018-03-27 F. Hoffmann-La Roche Ag Antibodies against human csf-1r and uses thereof
WO2011107553A1 (en) 2010-03-05 2011-09-09 F. Hoffmann-La Roche Ag Antibodies against human csf-1r and uses thereof
AR080698A1 (es) 2010-04-01 2012-05-02 Imclone Llc Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
CN107011438B (zh) * 2010-05-04 2020-11-20 戊瑞治疗有限公司 结合csf1r的抗体
TW201307845A (zh) 2010-12-13 2013-02-16 Novartis Ag 預測方法及利用ｉｌ－１７拮抗劑治療關節炎的方法
US20140288279A1 (en) 2011-10-21 2014-09-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) M-DC8+ Monocyte Depleting Agent for the Prevention or the Treatment of a Condition Associated with a Chronic Hyperactivation of the Immune System
US9139652B2 (en) 2011-10-21 2015-09-22 Transgene Sa Method for increasing M1 macrophages in a patient
AU2012374617B2 (en) * 2012-05-11 2015-09-17 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)
SG10201906328RA (en) * 2012-08-31 2019-08-27 Five Prime Therapeutics Inc Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
LT3212670T (lt) * 2014-10-29 2021-02-10 Five Prime Therapeutics, Inc. Kombinuotasis vėžio gydymas

Also Published As

Publication number Publication date
SG10201811475YA (en) 2019-02-27
EA201692482A1 (ru) 2017-05-31
WO2015200089A1 (en) 2015-12-30
EA037561B1 (ru) 2021-04-14
EP3157957A1 (en) 2017-04-26
MX391735B (es) 2025-03-21
IL249393B (en) 2022-02-01
US20170152320A1 (en) 2017-06-01
JP2020169179A (ja) 2020-10-15
CA2951156A1 (en) 2015-12-30
US10975153B2 (en) 2021-04-13
CN106795222A (zh) 2017-05-31
JP6964410B2 (ja) 2021-11-10
AU2015280362A1 (en) 2016-12-22
KR20230086809A (ko) 2023-06-15
CN113350501A (zh) 2021-09-07
US20210317219A1 (en) 2021-10-14
SG11201610672YA (en) 2017-01-27
AU2015280362B2 (en) 2021-03-04
KR20170016501A (ko) 2017-02-13
MX2016016664A (es) 2017-03-20
JP2017520562A (ja) 2017-07-27
IL249393A0 (en) 2017-02-28

Similar Documents

Publication Publication Date Title
CY1125032T1 (el) Υποκινητης mnd χιμαιρικους υποδοχεις αντιγονου
MX2017005553A (es) Terapia de combinacion para cancer.
CL2016002157A1 (es) Anticuerpos anti-cd38 para el tratamiento de leucemia linfoide aguda
MX2017013178A (es) Terapia de combinacion para cancer.
MX2017008218A (es) Anticuerpos anti-csf1r para tratar pvns.
EA202092435A2 (ru) Моноклональные антитела против bcma
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
CL2017002401A1 (es) Anticuerpos contra icos
BR112017007170A2 (pt) anticorpos anti-ox40 humanizados e suas utilizações
CY1118168T1 (el) Διπλα ειδικα αντισωματα εναντι cd3εψιλον και bcma
CL2019001381A1 (es) Método para el tratamiento de glomeruloesclerosis segmentaria focal.
CL2018000596A1 (es) Nuevos compuestos bicíclicos como inhibidores de la atx
LT3159409T (lt) Antiprasminė nukleorūgštis, skirta panaudoti diušeno raumenų distrofijos gydymui
CL2016000221A1 (es) Anticuerpos anti-fgfr2iiib afucosilados.
CL2018000649A1 (es) Nuevos compuestos bicíclicos como inhibidores duales de atx / ca
MX2017014191A (es) Metodos de tratamiento de una enfermedad neurodegenerativa.
FR3021455B1 (fr) Procede d'aplanissement d'evidements remplis de cuivre
EA201790643A1 (ru) Способ и устройство для непрерывного нанесения нанослоистых металлических покрытий
MX2018000778A (es) Metodos para tratar trastornos mediados por hepcidinas.
MX372543B (es) Moduladores de receptor nuclear.
BR112016029460A2 (pt) métodos para tratar artrite reumatoide
TW201713333A (en) Methods of treating a neurodegenerative disease
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof
TR201819099T4 (tr) Besleme malzemenin işlenmesi için düzenek ve yöntem.
EA201692246A1 (ru) Способ получения 2,6-диметилбензохинона

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.